Tcel receptor kinase6/11/2023 1994) T-cell development in ZAP-70 deficient mice is arrested at the transition from the CD4 + CD8 + double positive (DP) stage, Observations: ZAP-70-deficient patients have no functional T cells in their peripheral blood and suffer from severe combined The importance of ZAP-70, a cytoplasmic tyrosine kinase mainly expressed in T cells, was rapidly revealed by the following Was identified in TCR-stimulated Jurkat cells ( Chan et al. WeĪlso describe a model experimental system in which ZAP-70 function can be interrupted by a small chemical inhibitor.Īpproximately 18 years ago, a T-cell receptor (TCR)–ζ chain-associated 70 kDa tyrosine phosphoprotein (therefore termed ZAP-70) Here we review the structure of ZAP-70, its regulation, its role in development and in disease. PFS is significantly prolonged in those aged≤65 years and those with moderate and high expression of PD-L1. Conclusions: NSCLC patients who failed EGFR-TKIs treatment can tolerate adverse reactions related to immunotherapy combined with chemotherapy and bevacizumab treatment. Most of the treatment-related adverse reactions in the whole group were grade 1-2, including bone marrow suppression ( n=24), nausea ( n=25), decreased appetite ( n=24), fatigue ( n=22), vomiting ( n=18), abnormal liver function ( n=17), blood creatinine increased ( n=10), and so on. The median PFS of patients with low expression of programmed death receptor-ligand 1 (PD-L1) [Tumor cell Proportion Score (TPS)65 years old ( HR=4.017, 95% CI: 1.468-10.992, P=0.007) was a risk factor for PFS in NSCLC patients who received immunotherapy combined with chemotherapy and bevacizumab after EGFR-TKIs treatment failure. Eleven patients had partial response, 19 patients had stable disease and 30 patients had progressive disease. The age ranged from 41 to 75 years, with a median age of 61 years. Results: Among the 60 NSCLC patients, 22 were males. Cox proportional hazard regression models were utilized to analyze the influencing factors of progression-free survival (PFS). The survival curve was drawn by Kaplan-Meier method. The adverse reactions of patients were evaluated according to the common terminology criteria for adverse events. The response evaluation criteria in solid tumors were used to evaluate the short-term efficacy. Patients were followed up by telephone or outpatient review up to October 1, 2022, with a median follow-up of 8.2 months (95% CI: 7.1-9.3). Methods: A retrospective analysis was made on the clinical data of 60 NSCLC patients who were treated with immunotherapy combined with chemotherapy and bevacizumab after EGFR-TKIs treatment failure in the Affiliated Cancer Hospital of Shandong First Medical University from January 2019 to March 2022. Objective: To investigate the efficacy and influencing factors of immunotherapy combined with chemotherapy and bevacizumab in patients with non-small cell lung cancer (NSCLC) who failed epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment.
0 Comments
Leave a Reply. |